

Luigi Boiardi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11838883/publications.pdf>

Version: 2024-02-01

79
papers

5,250
citations

81900

39
h-index

85541

71
g-index

81
all docs

81
docs citations

81
times ranked

2978
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Polymyalgia Rheumatica and Giant-Cell Arteritis. <i>New England Journal of Medicine</i> , 2002, 347, 261-271. | 27.0 | 1,002 |
| 2 | Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2005, 53, 293-297. | 6.7 | 218 |
| 3 | Tocilizumab: a novel therapy for patients with large-vessel vasculitis. <i>Rheumatology</i> , 2012, 51, 151-156. | 1.9 | 203 |
| 4 | Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. <i>Arthritis and Rheumatism</i> , 1991, 34, 351-356. | 6.7 | 198 |
| 5 | Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: A prospective follow-up study. <i>Seminars in Arthritis and Rheumatism</i> , 2000, 30, 17-24. | 3.4 | 178 |
| 6 | Is Duplex Ultrasonography Useful for the Diagnosis of Giant-Cell Arteritis?. <i>Annals of Internal Medicine</i> , 2002, 137, 232. | 3.9 | 169 |
| 7 | Infliximab plus Prednisone or Placebo plus Prednisone for the Initial Treatment of Polymyalgia Rheumatica. <i>Annals of Internal Medicine</i> , 2007, 146, 631. | 3.9 | 158 |
| 8 | Inflamed Temporal Artery. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1360-1370. | 3.7 | 147 |
| 9 | Distal musculoskeletal manifestations in polymyalgia rheumatica: A prospective followup study. <i>Arthritis and Rheumatism</i> , 1998, 41, 1221-1226. | 6.7 | 141 |
| 10 | Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: A prospective followup study. <i>Arthritis and Rheumatism</i> , 2005, 53, 33-38. | 6.7 | 136 |
| 11 | Are polymyalgia rheumatica and giant cell arteritis the same disease?. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 33, 294-301. | 3.4 | 130 |
| 12 | Positron emission tomography (PET): Evaluation of chronic periaortitis. <i>Arthritis and Rheumatism</i> , 2005, 53, 298-303. | 6.7 | 128 |
| 13 | Visual loss and other cranial ischaemic complications in giant cell arteritis. <i>Nature Reviews Rheumatology</i> , 2017, 13, 476-484. | 8.0 | 121 |
| 14 | Performance of the new 2012 EULAR/ACR classification criteria for polymyalgia rheumatica: comparison with the previous criteria in a single-centre study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1190-1193. | 0.9 | 81 |
| 15 | Polymyalgia rheumatica. <i>Best Practice and Research in Clinical Rheumatology</i> , 2004, 18, 705-722. | 3.3 | 80 |
| 16 | Flares in Biopsy-Proven Giant Cell Arteritis in Northern Italy. <i>Medicine (United States)</i> , 2016, 95, e3524. | 1.0 | 78 |
| 17 | A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. <i>American Journal of Human Genetics</i> , 2017, 100, 64-74. | 6.2 | 78 |
| 18 | Small-vessel vasculitis surrounding an uninfamed temporal artery and isolated vasa vasorum vasculitis of the temporal artery: Two subsets of giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 549-556. | 6.7 | 69 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Difference in the expression of IL-9 and IL-17 correlates with different histological pattern of vascular wall injury in giant cell arteritis. <i>Rheumatology</i> , 2015, 54, 1596-1604. | 1.9 | 66 |
| 20 | Polymyalgia rheumatica. <i>Lancet</i> , The, 1997, 350, 43-47. | 13.7 | 64 |
| 21 | Contrast-enhanced Ultrasound of the Carotid Artery in Patients With Large Vessel Vasculitis: Correlation With Positron Emission Tomography Findings. <i>Arthritis Care and Research</i> , 2017, 69, 143-149. | 3.4 | 64 |
| 22 | Vascular endothelial growth factor gene polymorphisms in Behçet's disease. <i>Journal of Rheumatology</i> , 2004, 31, 1785-9. | 2.0 | 62 |
| 23 | Tocilizumab for polymyalgia rheumatica: Report of two cases and review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 43, 113-118. | 3.4 | 59 |
| 24 | Is colour duplex sonography-guided temporal artery biopsy useful in the diagnosis of giant cell arteritis? A randomized study. <i>Rheumatology</i> , 2015, 54, 400-404. | 1.9 | 58 |
| 25 | Relationship between interleukin 6 promoter polymorphism at position -174, IL-6 serum levels, and the risk of relapse/recurrence in polymyalgia rheumatica. <i>Journal of Rheumatology</i> , 2006, 33, 703-8. | 2.0 | 58 |
| 26 | Longitudinal examination with shoulder ultrasound of patients with polymyalgia rheumatica. <i>Rheumatology</i> , 2009, 48, 1566-1569. | 1.9 | 55 |
| 27 | IL-33 is overexpressed in the inflamed arteries of patients with giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 258-264. | 0.9 | 55 |
| 28 | Incidence, Prevalence, and Survival of Biopsy-Proven Giant Cell Arteritis in Northern Italy During a 26-Year Period. <i>Arthritis Care and Research</i> , 2017, 69, 430-438. | 3.4 | 55 |
| 29 | Treatment of refractory polymyalgia rheumatica with etanercept: An open pilot study. <i>Arthritis and Rheumatism</i> , 2007, 57, 1514-1519. | 6.7 | 52 |
| 30 | Brief Report: Interleukin-6 as an Inflammatory Mediator and Target of Therapy in Chronic Periaortitis. <i>Arthritis and Rheumatism</i> , 2013, 65, 2469-2475. | 6.7 | 51 |
| 31 | Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study. <i>Journal of Rheumatology</i> , 2003, 30, 760-3. | 2.0 | 50 |
| 32 | Vascular endothelial growth factor gene polymorphisms in giant cell arteritis. <i>Journal of Rheumatology</i> , 2003, 30, 2160-4. | 2.0 | 50 |
| 33 | Susceptibility and severity of COVID-19 in patients treated with bDMARDs and tsDMARDs: a population-based study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 986.2-988. | 0.9 | 49 |
| 34 | Comparison between colour duplex sonography findings and different histological patterns of temporal artery. <i>Rheumatology</i> , 2013, 52, 2268-2274. | 1.9 | 48 |
| 35 | Inflamed shoulder structures in polymyalgia rheumatica with normal erythrocyte sedimentation rate. <i>Arthritis and Rheumatism</i> , 2001, 44, 1155-1159. | 6.7 | 47 |
| 36 | Detection of parvovirus B19 DNA by polymerase chain reaction in giant cell arteritis: A case-control study. <i>Arthritis and Rheumatism</i> , 2002, 46, 3099-3101. | 6.7 | 45 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | HLA-DRB1 alleles associated with polymyalgia rheumatica in northern Italy: correlation with disease severity. <i>Annals of the Rheumatic Diseases</i> , 1999, 58, 303-308. | 0.9 | 44 |
| 38 | NKG2D stimulated T-cell autoreactivity in giant cell arteritis and polymyalgia rheumatica. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1852-1859. | 0.9 | 44 |
| 39 | Aortic dilatation in patients with large vessel vasculitis: A longitudinal case control study using PET/CT. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 1074-1082. | 3.4 | 40 |
| 40 | Endothelial nitric oxide synthase gene polymorphisms in Behçet's disease. <i>Journal of Rheumatology</i> , 2002, 29, 535-40. | 2.0 | 39 |
| 41 | Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study. <i>Rheumatology</i> , 2021, 60, 3851-3861. | 1.9 | 38 |
| 42 | MicroRNA markers of inflammation and remodelling in temporal arteries from patients with giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1527-1533. | 0.9 | 37 |
| 43 | Therapy with cyclosporine in psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 1997, 27, 36-43. | 3.4 | 35 |
| 44 | Endothelial nitric oxide synthase gene polymorphisms in giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2003, 48, 3219-3223. | 6.7 | 35 |
| 45 | No detection of varicella-zoster virus in temporal arteries of patients with giant cell arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 235-240. | 3.4 | 35 |
| 46 | Differential effects of anti-TNF- α drugs on fibroblast-like synoviocyte apoptosis. <i>Rheumatology</i> , 2010, 49, 480-489. | 1.9 | 34 |
| 47 | Correlations between histopathological findings and clinical manifestations in biopsy-proven giant cell arteritis. <i>Journal of Autoimmunity</i> , 2016, 69, 94-101. | 6.5 | 33 |
| 48 | Vascular endothelial growth factor production in polymyalgia rheumatica. <i>Arthritis and Rheumatism</i> , 2000, 43, 2472-2480. | 6.7 | 32 |
| 49 | Expression of interleukin-32 in the inflamed arteries of patients with giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2011, 63, 2097-2104. | 6.7 | 31 |
| 50 | Relapses and long-term remission in large vessel giant cell arteritis in northern Italy: Characteristics and predictors in a long-term follow-up study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 549-558. | 3.4 | 29 |
| 51 | Long-term remission in biopsy proven giant cell arteritis: A retrospective cohort study. <i>Journal of Autoimmunity</i> , 2017, 77, 39-44. | 6.5 | 27 |
| 52 | Histopathologic Findings of Patients With Biopsy-Negative Giant Cell Arteritis Compared to Those Without Arteritis: A Population-Based Study. <i>Arthritis Care and Research</i> , 2016, 68, 865-870. | 3.4 | 26 |
| 53 | Survival predictors in biopsy-proven giant cell arteritis: a northern Italian population-based study. <i>Rheumatology</i> , 2019, 58, 609-616. | 1.9 | 26 |
| 54 | Efficacy and safety of TNF- α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients. <i>Rheumatology</i> , 2022, 61, 1376-1384. | 1.9 | 26 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | Are steroids alone sufficient for the treatment of giant cell arteritis?. Best Practice and Research in Clinical Rheumatology, 2005, 19, 277-292. | 3.3 | 25 |
| 56 | Fat suppression magnetic resonance imaging in shoulders of patients with polymyalgia rheumatica. Journal of Rheumatology, 2004, 31, 120-4. | 2.0 | 24 |
| 57 | Tumor necrosis factor-alpha protects synovial cells from nitric oxide induced apoptosis through phosphoinositide 3-kinase Akt signal transduction. Journal of Rheumatology, 2006, 33, 1061-8. | 2.0 | 24 |
| 58 | Serum interleukin-6 receptor in polymyalgia rheumatica: A potential marker of relapse/recurrence risk. Arthritis and Rheumatism, 2008, 59, 1147-1154. | 6.7 | 23 |
| 59 | Significance of inflammation restricted to adventitial/periadventitial tissue on temporal artery biopsy. Seminars in Arthritis and Rheumatism, 2020, 50, 1064-1072. | 3.4 | 22 |
| 60 | Efficacy of infliximab in a patient with refractory idiopathic retroperitoneal fibrosis. Clinical and Experimental Rheumatology, 2012, 30, 776-8. | 0.8 | 22 |
| 61 | Unmet Needs in the Pathogenesis and Treatment of Vasculitides. Clinical Reviews in Allergy and Immunology, 2018, 54, 244-260. | 6.5 | 21 |
| 62 | Polymyalgia rheumatica. Lancet, The, 1996, 348, 550-551. | 13.7 | 20 |
| 63 | Increased expression of interleukin-22 in patients with giant cell arteritis. Rheumatology, 2018, 57, 64-72. | 1.9 | 20 |
| 64 | PLA1/A2 polymorphism of the platelet glycoprotein receptor IIIA and risk of cranial ischemic complications in giant cell arteritis. Arthritis and Rheumatism, 2007, 56, 3502-3508. | 6.7 | 18 |
| 65 | Association Between Specimen Length and Number of Sections and Diagnostic Yield of Temporal Artery Biopsy for Giant Cell Arteritis. Arthritis Care and Research, 2021, 73, 402-408. | 3.4 | 18 |
| 66 | Incidence and prevalence of large vessel vasculitis (giant cell arteritis and Takayasu arteritis) in northern Italy: A population-based study. Seminars in Arthritis and Rheumatism, 2021, 51, 786-792. | 3.4 | 16 |
| 67 | Do we need treatment with tumour necrosis factor blockers for giant cell arteritis?. Annals of the Rheumatic Diseases, 2007, 67, 577-579. | 0.9 | 13 |
| 68 | Adalimumab in Psoriatic Arthritis. Journal of rheumatology Supplement, The, 2012, 89, 77-81. | 2.2 | 10 |
| 69 | Geographical and genetic factors do not account for significant differences in the clinical spectrum of giant cell arteritis in southern europe. Journal of Rheumatology, 2004, 31, 520-3. | 2.0 | 10 |
| 70 | Giant cell arteritis in Mediterranean countries: Comment on the article by Salvarani et al. Arthritis and Rheumatism, 1992, 35, 1249-1250. | 6.7 | 9 |
| 71 | TLR-4 and VEGF Polymorphisms in Chronic Periaortitis. PLoS ONE, 2013, 8, e62330. | 2.5 | 8 |
| 72 | New indications for biological therapies. Internal and Emergency Medicine, 2011, 6, 1-9. | 2.0 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | The therapeutic potential of tuftsin-phosphorylcholine in giant cell arteritis. Journal of Autoimmunity, 2019, 98, 113-121. | 6.5 | 7 |
| 74 | Vessel inflammation and morphological changes in patients with large vessel vasculitis: a retrospective study. RMD Open, 2022, 8, e001977. | 3.8 | 7 |
| 75 | Multidisciplinary Focus on Cyclosporin A. Journal of rheumatology Supplement, The, 2009, 83, 52-55. | 2.2 | 5 |
| 76 | CC chemokine receptor 5 polymorphism in Italian patients with giant cell arteritis. Modern Rheumatology, 2013, 23, 851-855. | 1.8 | 3 |
| 77 | CC chemokine receptor 5 polymorphism in Italian patients with giant cell arteritis. Modern Rheumatology, 2013, 23, 851-855. | 1.8 | 2 |
| 78 | Response to "The Relevance of Restricted Inflammation in a TAB" by Griffin KJ et al.. Seminars in Arthritis and Rheumatism, 2021, 51, e8-e9. | 3.4 | 1 |
| 79 | Cardiac Involvement in Systemic Vasculitis. Handbook of Systemic Autoimmune Diseases, 2003, 1, 227-254. | 0.1 | 0 |